Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Abbvie 1Q Results | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Abbvie 1Q Results

Global Humira sales down 36%, while Skyrizi and Rinvoq sales were up 48% and 59%, respectively.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Abbvie
1Q Revenues: $12.3 billion (+1%)
1Q Earnings: $1.4 billion (earnings were $239 million 1Q23)
Comments: Immunology portfolio sales were $5.4 billion, down 4% in the quarter. Global Humira sales were $2.3 billion down 36%. Global Skyrizi revenues were $2.0 billion, an increase of 48% and global Rinvoq revenues were $1.1 billion, an increase of 59%. Oncology portfolio sales were $1.5 billion, an increase of 9%. Global Imbruvica sales were $838 million, down 5%. Global Venclexta sales were $614 million, up 14%. Global Elahere sales were $64 million, reflecting a partial quarter of sales based on the February 2024 close date of the ImmunoGen acquisition. Global neuroscience portfolio sales were $1.96 billion, an increase of 16%. Global Botox Therapeutic sales were $748 million, up 4%. Global Vraylar sales were $694 million, up 24%. Global Ubrelvy revenues were $203 million, an increase of 34%. Global Qulipta sales were $131 million, an increase of 98%. Global revenues from the aesthetics portfolio were $1.2 billion, a decrease of 4%.
Global Botox Cosmetic sales were $633 million, down 4%. Global Juvederm revenues were $297 million, a down 16%.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters